Evolus Inc (NASDAQ:EOLS) was the recipient of unusually large options trading on Thursday. Traders acquired 2,135 call options on the stock. This is an increase of 1,343% compared to the typical volume of 148 call options.
Hedge funds have recently added to or reduced their stakes in the business. Patriot Financial Group Insurance Agency LLC boosted its stake in Evolus by 50.0% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 1,500 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in Evolus by 48.9% during the 1st quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock valued at $39,000 after purchasing an additional 569 shares during the last quarter. Pearl River Capital LLC boosted its stake in Evolus by 217.7% during the 1st quarter. Pearl River Capital LLC now owns 1,906 shares of the company’s stock valued at $44,000 after purchasing an additional 1,306 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Evolus by 8,877.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,975 shares of the company’s stock valued at $45,000 after purchasing an additional 1,953 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY acquired a new position in Evolus during the 1st quarter valued at about $83,000. Institutional investors and hedge funds own 19.33% of the company’s stock.
EOLS stock traded down $2.14 during mid-day trading on Friday, reaching $16.25. 55,940 shares of the company traded hands, compared to its average volume of 495,080. The company has a market capitalization of $510.52 million, a P/E ratio of -10.17 and a beta of 5.01. The company has a debt-to-equity ratio of 0.96, a quick ratio of 14.52 and a current ratio of 14.80. Evolus has a fifty-two week low of $10.22 and a fifty-two week high of $39.50.
Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Tuesday, April 30th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.11). As a group, sell-side analysts forecast that Evolus will post -3.06 earnings per share for the current fiscal year.
EOLS has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Evolus in a research report on Thursday, February 14th. They issued a “buy” rating and a $37.00 target price for the company. Zacks Investment Research lowered Evolus from a “hold” rating to a “sell” rating in a research report on Tuesday, February 5th. Mizuho boosted their target price on Evolus from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research report on Tuesday, March 19th. Finally, SunTrust Banks initiated coverage on Evolus in a research report on Wednesday, March 20th. They issued a “buy” rating and a $30.00 target price for the company. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $30.71.
ILLEGAL ACTIVITY WARNING: “Evolus Sees Unusually High Options Volume (EOLS)” was published by Modern Readers and is owned by of Modern Readers. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.modernreaders.com/news/2019/05/17/evolus-sees-unusually-high-options-volume-eols.html.
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More: What is a trade deficit?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.